Efficacy of aspirin for sporadic vestibular schwannoma: a meta-analysis.

Saved in:

Bibliographic Details
Title:	Efficacy of aspirin for sporadic vestibular schwannoma: a meta-analysis.
Authors:	Ignacio, Katrina Hannah D. (AUTHOR), Espiritu, Adrian I. (AUTHOR), Diestro, Jose Danilo B. (AUTHOR), Chan, Kevin Ivan (AUTHOR), Dmytriw, Adam A. (AUTHOR), Omar II, Abdelsimar T. (AUTHOR)
Source:	Neurological Sciences. Dec2021, Vol. 42 Issue 12, p5101-5106. 6p. 1 Diagram, 1 Chart, 1 Graph.
Subjects:	Acoustic neuroma, Aspirin, Stereotaxic techniques, Tumor growth, Stereotactic radiotherapy, Randomized controlled trials
Abstract:	Background: Pharmacologic treatment of vestibular schwannomas (VSs) may increase the success of conservative management for small lesions, and offer an alternative to surgery and stereotactic radiotherapy in symptomatic cases in the high-risk population. Agents that have been studied include aspirin (ASA), but the results of the preliminary studies have been conflicting. In this study, we aimed to systematically review the evidence on the effect of ASA intake on tumor growth in patients with VSs. Methods: Pubmed, Cochrane, Scopus, Embase, ClinicalTrials.gov, and Web of Science were searched for studies comparing VS tumor growth in patients with aspirin intake and those without. Random-effect meta-analysis was used to evaluate the outcomes in terms of linear and/or volumetric tumor growth. Results: Four retrospective cohort studies were included in the meta-analysis. No significant difference was found in tumor growth between VS patients with aspirin intake and those without. This result held true for the analysis of linear tumor growth (OR 1.23; 95% CI 0.49, 3.10), volumetric tumor growth (OR 1.41; 95% CI 0.36, 5.59), and both combined (OR 1.02; 95% CI 0.56, 1.86). Conclusions: Our meta-analysis suggests that there is insufficient evidence to recommend ASA therapy in patients with VSs. High-quality randomized controlled trials are warranted to determine the efficacy of this drug in reducing VS tumor growth. [ABSTRACT FROM AUTHOR]
	Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Psychology and Behavioral Sciences Collection

Description
Abstract:	Background: Pharmacologic treatment of vestibular schwannomas (VSs) may increase the success of conservative management for small lesions, and offer an alternative to surgery and stereotactic radiotherapy in symptomatic cases in the high-risk population. Agents that have been studied include aspirin (ASA), but the results of the preliminary studies have been conflicting. In this study, we aimed to systematically review the evidence on the effect of ASA intake on tumor growth in patients with VSs. Methods: Pubmed, Cochrane, Scopus, Embase, ClinicalTrials.gov, and Web of Science were searched for studies comparing VS tumor growth in patients with aspirin intake and those without. Random-effect meta-analysis was used to evaluate the outcomes in terms of linear and/or volumetric tumor growth. Results: Four retrospective cohort studies were included in the meta-analysis. No significant difference was found in tumor growth between VS patients with aspirin intake and those without. This result held true for the analysis of linear tumor growth (OR 1.23; 95% CI 0.49, 3.10), volumetric tumor growth (OR 1.41; 95% CI 0.36, 5.59), and both combined (OR 1.02; 95% CI 0.56, 1.86). Conclusions: Our meta-analysis suggests that there is insufficient evidence to recommend ASA therapy in patients with VSs. High-quality randomized controlled trials are warranted to determine the efficacy of this drug in reducing VS tumor growth. [ABSTRACT FROM AUTHOR]
ISSN:	15901874
DOI:	10.1007/s10072-021-05193-3